LOGIN
ID
PW
MemberShip
2025-07-01 18:54
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Policy
Yoon Kim ¡®40% of the generic drug price is a bubble¡¯
by
Lee, Jeong-Hwan
Oct 10, 2024 05:50am
Kyoo-hong Cho, the Minister of Health and Welfare, positively responded to Democratic Party of Korea Representative Yoon Kim's request to lower the price of generic versions of patent-expired drugs within the year. This refers to a separate generic drug price cut rather than the foreign drug price referencing reevaluations, which the phar
Policy
Daewoong wins nod for first generic version of Ibrance tab
by
Lee, Tak-Sun
Oct 8, 2024 05:49am
Daewoong's first generic for Pfizer's breast cancer treatment, 'Ibrance Tab,' has been approved. Due to the successful patent nullification, the company received priority marketing authorization. The first generic can be launched in March 23rd, 2027, when the product patent expires. The Ministry of Food and Drug Safety (MFDS) has granted
Policy
Drugs for NSCLC harboring MET alterations pass CDRC review
by
Lee, Tak-Sun
Oct 7, 2024 05:48am
A treatment for non-small cell lung cancer (NSCLC) harboring MET alterations has passed the first stage for reimbursement coverage by national health insurance. Merk's Tepmetko is the drug that passed. On October 2nd, the Cancer Disease Review Committee (CDRC) of the Health Insurance Review and Assessment Service (HIRA) commenced the 7th m
Policy
'Qarziba' to be reconsidered for the DREC review in KOR
by
Lee, Tak-Sun
Oct 7, 2024 05:48am
Qarziba (dinutuximab, Recordati Korea), which was designated as the 1st drug for a "Pilot Project for Integration of Product Approvals, Reimbursement Coverage Reviews, and Drug Price Negotiations" will be reconsidered for the Drug Reimbursement Evaluation Committee (DREC) review. Qarziba was considered for the DREC review in August but re
Policy
EUA for Novavax's COIVD-19 vaccine targeting the variant
by
Lee, Hye-Kyung
Oct 2, 2024 05:49am
The Ministry of Food and Drug Safety (Minister Oh Yu-kyoung, MFDS) announced emergency use authorization of Novavax's 'COVID-19 Vaccine corresponding to JN.1 strain of SARS-CoV-2 (2024-2025 Formula).' The emergency use authorization is a system designed to respond appropriately to a public health crisis, including infectious disease pande
Policy
"Hundreds of doctors have received pharmaceutical rebates"
by
Kang, Shin-Kook
Sep 30, 2024 05:47am
After conducting a tax audit of 16 pharmaceutical companies, Korea's National Tax Service (NTS) announced that it would impose an income tax for doctors who received rebates. The NTS mentioned that over hundreds of doctors received rebates, and rebate-associated medical-pharmaceutical cartels became a significant issue. As a result, the NTS w
Policy
Stelara biosimilar Steqeyma IV approved for use in Korea
by
Lee, Hye-Kyung
Sep 30, 2024 05:46am
Upon receiving approval for ¡®Steqeyma IV,¡¯ a biosimilar version of the autoimmune disease treatment Stelara (ustekinumab), Celltion has now received approval for all its Steqeyma formulations. By adding the interleukin (IL) inhibitor option to the existing family of tumor necrosis factor (TNF)-¥á inhibitors, which includes Remsima, Rems
Policy
COVID-19 drugs to be reimbursable, "KRW 50,000 co-payment"
by
Lee, Jeong-Hwan
Sep 27, 2024 05:53am
The National Health Insurance will cover two COVID-19 treatments, Paxlovid and Veklury, starting on October 1st. The government will list COVID-19 treatments for reimbursement and make a policy revision to support the patient co-payment at the previous price of KRW 50,000. The National Health Insurance coverage for Takeda Pharmaceutica
Policy
2nd Approval-Evaluation-Negotiation pilot project imminent
by
Kim, Jin-Gu
Sep 26, 2024 05:51am
The initiation of the 2nd pilot project for the ¡®approval-evaluation-negotiation linkage system,¡¯ which was introduced to shorten the time from drug approval to reimbursement, is imminent. The Ministry of Health and Welfare has completed receiving drug submissions for the 2nd pilot project from pharmaceutical companies and is in the final revi
Policy
Higher dosage Eylea expected to strike back at biosimilars
by
Lee, Tak-Sun
Sep 26, 2024 05:51am
The competition in the market for the macular degeneration drug Eylea has recently intensified with Samsung Bioepis and Celltrion, which have recently launched biosimilars. The original developer is set to strike back against the competitors. Bayer will release Eylea Inj 8 mg (aflibercept), with an extended treatment interval, into the
<
21
22
23
24
25
26
27
28
29
30
>